C4 Therapeutics Inc. (CCCC): Price and Financial Metrics

C4 Therapeutics Inc. (CCCC): $4.05

0.03 (-0.74%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add CCCC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#282 of 348

in industry

CCCC Price/Volume Stats

Current price $4.05 52-week high $11.88
Prev. close $4.08 52-week low $1.06
Day low $3.92 Volume 1,558,000
Day high $4.07 Avg. volume 2,851,905
50-day MA $5.87 Dividend yield N/A
200-day MA $5.03 Market Cap 278.66M

CCCC Stock Price Chart Interactive Chart >


C4 Therapeutics Inc. (CCCC) Company Bio


C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.


CCCC Latest News Stream


Event/Time News Detail
Loading, please wait...

CCCC Latest Social Stream


Loading social stream, please wait...

View Full CCCC Social Stream

Latest CCCC News From Around the Web

Below are the latest news stories about C4 THERAPEUTICS INC that investors may wish to consider to help them evaluate CCCC as an investment opportunity.

The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics

Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 28, 2023

11 Hot Healthcare Stocks To Buy Now

In this article, we will be taking a look at 11 hot healthcare stocks to buy now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Hot Healthcare Stocks To Buy Now. Healthcare is a vital part of daily living for everyone, whether it be to cure […]

Yahoo | December 28, 2023

Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet

The mean of analysts' price targets for C4 Therapeutics, Inc. (CCCC) points to a 223% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 15, 2023

Following a 38% decline over last year, recent gains may please C4 Therapeutics, Inc. (NASDAQ:CCCC) institutional owners

Key Insights Institutions' substantial holdings in C4 Therapeutics implies that they have significant influence over the company's share price The top 9 shareholders own 51% of the company Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business

Yahoo | December 14, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching!

William White on InvestorPlace | December 13, 2023

Read More 'CCCC' Stories Here

CCCC Price Returns

1-mo -30.17%
3-mo -50.73%
6-mo -9.19%
1-year 40.63%
3-year -89.44%
5-year N/A
YTD -28.32%
2023 -4.24%
2022 -81.68%
2021 -2.81%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!